Literature DB >> 3493261

Suppression of anti-DNA antibody synthesis in vitro by a cross-reactive antiidiotypic antibody.

A Epstein, M Greenberg, B Diamond, A I Grayzel.   

Abstract

An understanding of the regulatory mechanisms that govern the humoral immune response will be facilitated by the availability of techniques for the measurement of specific antibody production in vitro. We have developed an enzyme-linked immunosorbent assay system for the measurement of in vitro anti-DNA antibody production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus. Using this technique, the PBMC from 74% of serologically active SLE patients produced levels of anti-DNA antibodies that were greater than 2 SD above the mean of 18 +/- 9 IU/ml for normal subjects. Furthermore, the addition of 3I, a monoclonal anti-idiotypic antibody that recognizes a cross-reactive determinant on anti-DNA antibodies, was shown to specifically inhibit anti-DNA production in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493261      PMCID: PMC424259          DOI: 10.1172/JCI112912

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  9 in total

1.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

2.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

3.  Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus.

Authors:  N I Abdou; H Wall; H B Lindsley; J F Halsey; T Suzuki
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

4.  Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

Authors:  W J Koopman; R E Schrohenloher; J C Barton; E C Greenleaf
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

5.  Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA.

Authors:  B H Hahn; F M Ebling
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

6.  Spontaneous production of antibodies to deoxyribonucleic acids in patients with systemic lupus erythematosus.

Authors:  T Takeuchi
Journal:  Clin Immunol Immunopathol       Date:  1985-04

7.  Studies on autoantibodies to deoxyribonucleic acid and deoxyribonucleoprotein with enzyme-immunoassay (ELISA).

Authors:  S P Halbert; J Karsh; M Anken
Journal:  J Lab Clin Med       Date:  1981-01

8.  Use of monoclonal antibodies to identify shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus.

Authors:  G Solomon; J Schiffenbauer; H D Keiser; B Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

9.  Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes.

Authors:  T Takeuchi; O Hosono; J Koide; M Homma; T Abe
Journal:  Arthritis Rheum       Date:  1985-08
  9 in total
  8 in total

1.  Incidence of anti-DNA idiotype-positive cells in human peripheral blood.

Authors:  O Takai; T Sasaki; T Muryoi; N Harata; H Hashimoto; K Yoshinaga
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

2.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

3.  Binding specificity of antiidiotypic autoantibodies to anti-DNA antibodies in humans.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; H Saito; K Yoshinaga
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

4.  Primary sequence and location of the idiotopes of V-88, a DNA-binding monoclonal autoantibody, determined by idiotope scanning with synthetic peptides on pins.

Authors:  N A Staines; F J Ward; A N Denbury; J Mitchiner; O Hartley; D Eilat; D A Isenberg; S Bansal
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

5.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

6.  Anti-idiotype and immunosuppressant treatment of murine lupus.

Authors:  C Morland; J Michael; D Adu; T Kizaki; A J Howie; A Morgan; N A Staines
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

7.  Antibodies elicited by pneumococcal antigens bear an anti-DNA--associated idiotype.

Authors:  A Grayzel; A Solomon; C Aranow; B Diamond
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  Involvement in lupus disease of idiotypes Id.F-423 and Id.IV-228 defined, respectively, upon foetal and adult MRL/Mp-lpr/lpr DNA-binding monoclonal autoantibodies.

Authors:  C T Ravirajan; N A Staines
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.